FDA Approval Alert: The Need-to-Know | Acalabrutinib Plus Bendamustine/Rituximab in Previously Untreated MCL

In January 2025, the FDA approved acalabrutinib plus bendamustine and rituximab for patients with previously untreated mantle cell lymphoma who are not eligible for autologous hematopoietic stem cell transplantation.

Acalabrutinib Plus Chemotherapy Provides Cover for High-Risk Patients in MCL
Acalabrutinib Plus Chemotherapy Provides Cover for High-Risk Patients in MCL
Video
Jan 17, 2025 6:00 PM
“Some of the early data that came out of the [ECHO] trial that led to this approval does suggest that it may be beneficial in some high-risk patients,” Tycel Phillips, MD, said.
FDA Approves Acalabrutinib Combo in Previously Untreated MCL
FDA Approves Acalabrutinib Combo in Previously Untreated MCL
Article
Jan 16, 2025 10:44 PM
The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.